Peer-reviewed veterinary case report
L-LOP and L-LOPP chemo for canine gut and liver lymphoma
By Yuwen Lai et al.·Published in Frontiers in Veterinary Science·2024·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: L-LOP/LOPP for the treatment of canine gastrointestinal/hepatosplenic lymphoma
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with gastrointestinal (GI) or hepatosplenic (HS) lymphoma, which are rare and aggressive types of cancer, were treated with a new chemotherapy protocol called L-LOP or L-LOPP. These treatments were generally well tolerated, with few serious side effects. On average, dogs with GI lymphoma lived for about 93 days after starting treatment, while those with HS lymphoma had a median survival of 210 days. Although the prognosis for these types of lymphoma is usually poor, this study suggests that the L-LOP/LOPP protocols may offer some benefit.
People also search for: dog lymphoma treatment · canine gastrointestinal cancer prognosis · hepatosplenic lymphoma in dogs
Abstract
Canine gastrointestinal (GI) and hepatosplenic (HS) high-grade (large cell) lymphomas are uncommon forms of canine lymphomas, with a very poor response to chemotherapy and a very poor prognosis. Currently, there are no established effective chemotherapy protocols for canine GI/HS lymphomas. This case series aimed to retrospectively evaluate the efficacy of lomustine-based protocols L-LOP (L-asparaginase, lomustine, vincristine, and prednisolone) and L-LOPP (with the addition of procarbazine) for treatment of canine GI/HS lymphomas. Medical records of dogs with cytologically or histologically diagnosed lymphoma at CityU Veterinary Medical Centre from 2019 to 2022 were retrospectively reviewed. The L-LOP/LOPP treatment protocol was well tolerated with rare severe adverse events. Median progression-free survival for GI and HS lymphoma was 56 days (range, 10–274 days) and 57 days (range 8–135 days) respectively; while median survival time for GI and HS lymphoma was 93 days (range 10–325 days) and 210 days (range 8–240 days) respectively.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/38846784